In this article, we are going to take a look at where Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC's ...
Zacks Small Cap Research on MSN1d
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Short interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) increased during the last reporting period, rising from 9.33M to 9.39M. This put 8.86% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback